Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy

Clinical and Experimental Immunology

Volumn 121, Issue 3, 2000, Pages 453-457

  Wakelkamp, I M M J ^a   Gerding, M N ^a   Van Der Meer, J W C ^a   Prummel, M F ^a   Wiersinga, W M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Graves' ophthalmopathy; IL 1RA; IL 6; IL 6R; SCD30; SIL 2R; Smoking; Thyr oid disease; TNF R

Indexed keywords

CD30 ANTIGEN; CYTOKINE RECEPTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; THYROID DISEASE;

ADULT; ANTIGENS, CD; ANTIGENS, CD30; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GRAVES DISEASE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIALOGLYCOPROTEINS; SMOKING; TH1 CELLS; TH2 CELLS;

EID: 0033858620     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01335.x     Document Type: Article

References (39)

1. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy
2. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management
3. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease
4. Retroocular fibroblasts: Important effector cells in Graves' ophthalmopathy
5. Thyroid-associated eye disease: Pathophysiology
6. Connective tissue, glycosaminogly-cans, and diseases of the thyroid
7. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts
8. Modulation of Graves' orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists
9. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy
10. Pathogenesis of Graves' ophthalmopathy: Recent controversies and progress
11. Graves' immunoglobulins and cytokines stimulate the expression of intercellular adhesion molecule-1 (ICAM-1) in cultured Graves' orbital fibroblasts
12. Anti-heat shock protein (hsp)72 antibodies are present in patients with Graves' disease (GD) and in smoking control subjects
13. Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy
14. Pathogenesis of Graves' ophthalmopathy
15. Cell-mediated or humoral immunity in Graves' ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue
16. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy
17. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy
18. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals
19. Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment
20. Increased serum concentra-tions of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease
21. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis
22. Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy
23. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves ophthalmopathy undergoing orbital radiotherapy
24. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia
25. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo
26. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy
27. CD30-mediated signaling promotes the development of human T helper type 2-like T cells
28. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines
29. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy
30. The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy
31. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach
32. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy
33. HLA-DPB1 polymorphisms in patients with hyperthyroid Graves' disease and early onset myasthenia gravis
34. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy
35. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO)
36. Association between Graves' ophthalmopathy and smoking
37. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin
38. Smoking and risk of Graves' disease
39. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: Possible role in thyroid-associated ophthalmopathy